Stockreport

Travere Therapeutics Reports Third Quarter 2024 Financial Results

Travere Therapeutics, Inc.  (TVTX) 
PDF FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN Type C meeting s [Read more]